Lynda Charters

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

The FDA granted orphan drug designation to BRM424 (BRIM Biotechnology) to treat neurotrophic keratitis (NK).

According to the authors, a patient with bilateral choroid metastases from breast cancer experienced "a dramatic response" after a combination treatment of abemaciclib and fulvestrant.

Teplizumab may work by binding to certain immune system cells that attack insulin-producing cells and increase the proportion of cells that help moderate the immune response, thus delaying progression to stage 3 type 1 diabetes.

The main outcome measures were the baseline cataract severity and self-reported cataract surgery at a 15-year visit.

Obesity can affect retinal structures differently.

This research collaboration between Chinese and Australian researchers set out to investigate the connection in the UK Biobank Study cohort.

It was reported that the more individuals smoke, the faster the retinal nerve fiber layer (RNFL) becomes thinner.

Awareness of visual impairment in clinical practice is suboptimal, and adherence to ophthalmologic evaluation needs to be improved. The prospective cohort study in the Netherlands included 170 children aged 0 to 18 years with a newly diagnosed brain tumor.

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

Treatment suspension has negative impact on visual function.

Several risk factors beyond intraocular pressure contribute to open-angle glaucoma.

The web-based, self-guided software application is accessed through touchscreen mobile devices.

A recent report shows that 61 drugs were associated with the development of acute angle-closure (AAC) glaucoma.

Potential for treatment strategy to prevent blindness from glaucoma.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all tertiles.

Spanish investigators recently reported the case of a 42-year-old man with monkeypox presenting with conjunctivitis.

The treatment of vision problems can help improve the quality of life for many people in the city.

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Optometrists are seeing recent advances in topical therapies that entered the market following decades of reliance of traditional single-agent drops. An implantable device that facilitates the slow release of drug is changing the landscape in glaucoma therapy.

Michael Chaglasian, OD, Illinois College of Optometry, Chicago, and Eric Schmidt, OD, Omni Eye Specialists, Wilmington, NC, share guidelines for ODs on diagnosing glaucoma during the 2022 Vision Expo West in Las Vegas.

Those who use oral contraceptives have improved dry eye symptoms, according to research.

Low prediction errors from 2 evaluated formulas shows promise for accurate prediction of IOL formulas in high myopic patients.

The jury is still out on whether wearing glasses is associated with a decreased risk of COVID-19 infections.

These new testing kits permit more equitable access to coronavirus testing.

Japanese researchers conducted a systematic review that identified clinical features and host factors associated with corneal allograft rejection after COVID-19 vaccination.

A recent study shows US adults with hearing and visual impairments have lower rates of vaccination for the coronavirus.

Researchers in Tokyo found that nearly 50% of preschoolers are myopic, indicating that the disease has reached epidemic proportions.

Establish a program in your practice during this Wild West phase of tech.

A 35-year-old woman presents with ptosis of the right eyelid 4 days after undergoing injection of botulinum toxin type A.